Search

First-in-class type 2 diabetes treatment Glyxambi® (empagliflozin/linagliptin) tablets for adults now available in U.S. pharmacies

Jardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway

Final analysis of the observational GioTag study: Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small cell lung cancer

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

New Type 2 Diabetes Treatment Synjardy® (empagliflozin/metformin hydrochloride) Tablets Now Available in U.S. Pharmacies

Linagliptin Demonstrated Significant HbA1c Reduction in Elderly People With Type 2 Diabetes With Inadequate Glycemic Control

Combating The Rise of Heartworm Disease in Dogs | Boehringer Ingelheim US

Click to read more on the Boehringer Ingelheim initiative to combat the rising incidence rates of heartworm disease in dogs by over half a million.

BI Cares Signature Program: Empowering Patients to Make Healthy Lifestyle Changes

Signature Program

PetPro Connect: Veterinary Medicine in the Digital Age

Read more on PetPro Connect - the BI app & web portal, linking pet owners and veterinarians in a world transformed by digital health and new medicine.

Oncology & Cancer Immunology

U.S. FDA approves Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) tablets for adults with type 2 diabetes

Heartworm Disease Prevention Initiative | Boehringer Ingelheim USheartworm disease prevention through its Heartworm 2020 initiative

Read more on how the Boehringer Ingelheim heartworm disease prevention initiative has helped more than 51,000 dogs receive care across the USA in 2020.

First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

Coliform Mastitis: the facts to know | Boehringer Ingelheim US

Click here to learn more about different management practices that can help you to improve your dairy herd's bottom line and productivity.

Oncology & Cancer Immunology

Heart Failure

Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

Boehringer Ingelheim Office Hours

How Much Do You Know About PPID? | Boehringer Ingelheim US

Click here to find out more about some of the common misconceptions you might have about pituitary pars intermedia dysfunction (PPID).

4 Possible Signs of Diabetes in Cats | Boehringer Ingelheim US

Click here to read more on the possible signs of diabetes in your feline friends, including how to identify and prevent potential symptoms and risks.

BI & Gubra Join Forces to Identify Peptides | Boehringer Ingelheim US

BI & Gubra announce research & licensing agreement focused on the identification & validation of targets & peptide compounds for the treatment of obesity.

Once-Daily Dosing for Most Diabetic Dogs | Boehringer Ingelheim US

Find out more on the BI PROZINC® (protamine zinc recombinant human insulin) for most canine diabetics, a breakthrough for pet owners with diabetic dogs.

Retinal Health

A future without pills – could AI change the way we treat psychiatric diseases?

Dr Cornelia Dorner-Ciossek talks about how her work with smartphone tech could transform how we treat mental illness.

Fighting Rabies in Madagascar | Boehringer Ingelheim US

Find out more about the Boehringer Ingelheim efforts to fight Rabies in Madagascar. Hear from a veterinarian who administered 75,000 vaccines to cats & dogs on the island.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

First-in-class type 2 diabetes treatment Glyxambi® (empagliflozin/linagliptin) tablets for adults now available in U.S. pharmacies

Jardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway

Final analysis of the observational GioTag study: Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small cell lung cancer

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

New Type 2 Diabetes Treatment Synjardy® (empagliflozin/metformin hydrochloride) Tablets Now Available in U.S. Pharmacies

Linagliptin Demonstrated Significant HbA1c Reduction in Elderly People With Type 2 Diabetes With Inadequate Glycemic Control

Combating The Rise of Heartworm Disease in Dogs | Boehringer Ingelheim US

BI Cares Signature Program: Empowering Patients to Make Healthy Lifestyle Changes

PetPro Connect: Veterinary Medicine in the Digital Age

Oncology & Cancer Immunology

U.S. FDA approves Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) tablets for adults with type 2 diabetes

Heartworm Disease Prevention Initiative | Boehringer Ingelheim USheartworm disease prevention through its Heartworm 2020 initiative

First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

Coliform Mastitis: the facts to know | Boehringer Ingelheim US

Oncology & Cancer Immunology

Heart Failure

Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

Boehringer Ingelheim Office Hours

How Much Do You Know About PPID? | Boehringer Ingelheim US

4 Possible Signs of Diabetes in Cats | Boehringer Ingelheim US

BI & Gubra Join Forces to Identify Peptides | Boehringer Ingelheim US

Once-Daily Dosing for Most Diabetic Dogs | Boehringer Ingelheim US

Retinal Health

A future without pills – could AI change the way we treat psychiatric diseases?

Fighting Rabies in Madagascar | Boehringer Ingelheim US